@article{JTD25896,
author = {Conal Hayton and Christopher Craig and Nazia Chaudhuri},
title = {Treatment of severe idiopathic pulmonary fibrosis—is sildenafil the next (in)stage?},
journal = {Journal of Thoracic Disease},
volume = {11},
number = {2},
year = {2018},
keywords = {},
abstract = {Despite progress in the therapeutic management of idiopathic pulmonary fibrosis (IPF) in the last decade, prognosis remains poor (1). This is particularly true of patients with severe disease, with 3-year mortality predicted at 76.8% for patients with advanced disease (2). Therapeutic trials in IPF typically exclude such patients which can subsequently have a significant impact on drug availability in the clinical setting. There is a desperate unmet need for treatment options in this advanced disease cohort.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25896}
}